Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorWomen's Hospital School Of Medicine Zhejiang University
About this trial
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility criteria
Qualifiers
Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
Positive PD-L1 expression;
ECOG score ≤1
Disqualifiers
Positive parametrium or surgical margin;
Incomplete radical surgery;
Residual target lesions;
Active autoimmune disease or autoimmune disease requiring systemic treatment;
Trial design
Treatments tested in this trial
- Camrelizumab combined with chemotherapy
Treatment groups
59 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov